Translating Molecular Insights Into Practice for HR-Positive/HER2-Negative Metastatic Breast Cancer Authors: Hope Rugo, MD; Peter A. Fasching, MD

https://www.medscape.org/viewarticle/translating-molecular-insights-practice-hr-positive-her2-2026a1000y0g?page=1&src=mkm_driv_cust_mscpedu_261105-12384304&uac=148436CN

Refining Adjuvant Therapy in HR-Positive/HER2-Negative Early Breast Cancer: Personalizing Care in the CDK4/6 Inhibitor Era Authors: Nadia Harbeck, MD, PhD; Frédérique Penault-Llorca, MD; Giampaolo Bianchini, MD; Henry Cain, MBChB, FRCS, MD; Janice Walshe, MB BCh, BAO, MRCPI

https://www.medscape.org/viewarticle/refining-adjuvant-therapy-hr-positive-her2-negative-early-2026a1000ysl?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_261105-OUS-HONC-refining-adjuvant-therapy-hr-positive-her2-negative-early-2026a1000ysl-cta

American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2026

https://www.medscape.com/c25/p14/american-association-neuromuscular-electrodiagnostic-2026a1000qkl?ecd=wnl_conf_neuro_AANEM_SPON_261105_mscpedit_etid8871049&uac=148436CN&impID=8871049

Advancing Care in HER2-Mutated NSCLC: Evidence, Diagnostics, and Future Directions Authors: Balazs Halmos, MD, MS

https://www.medscape.org/viewarticle/advancing-care-her2-mutated-nsclc-evidence-diagnostics-and-2026a1000d6g?page=1&src=mkmcmr_driv_stan_mscpedu_261105-OUS-HONC-advancing-care-her2-mutated-nsclc-evidence-diagnostics-and-2026a1000d6g-cta&uac=148436CN

Medical Device Cybersecurity

https://www.fda.gov/medical-devices/medical-device-cybersecurity?utm_medium=email&utm_source=govdelivery FDA Enhances Medical Device Cybersecurity Web Content The U.S. Food and Drug Administration has updated its medical device cybersecurity webpages to make key information and resources easier to find and use. What’s new: Refreshed main page within the Medical Devices section, with improved visibility and usability. Updated Guidance and FAQs with current information. Two new webpages with resources on securing medical devices and information about cybersecurity collaborations. Explore the updated content to find resources and information to help address cybersecurity considerations for medical devices.

Brown fat may benefit cardiovascular, psychiatric health

https://www.nih.gov/news-events/nih-research-matters/brown-fat-may-benefit-cardiovascular-psychiatric-health Brown fat may benefit cardiovascular, psychiatric health At a Glance Researchers found brown fat activity was linked to lower odds of cardiometabolic and psychiatric diseases. A blood pressure medication boosted brown fat activity in mice, which suggests existing drugs could be repurposed to activate brown fat. 3D illustration of brown fat cell. Brown fat cells contain many mitochondria (light-brown elongated ovals), which burn energy to create heat. Love Employee / Shutterstock Brown fat burns energy to produce heat. This is different from white fat, which stores energy in the body. Brown fat reserves are found deep in the neck, thorax, armpits, and along the spine. The amount of brown fat in humans varies by factors such as age, sex, and body-mass index.

Senescence-targeting nanoparticles may enhance immunotherapy

https://www.nih.gov/news-events/nih-research-matters/senescence-targeting-nanoparticles-may-enhance-immunotherapy Senescence-targeting nanoparticles may enhance immunotherapy At a Glance Researchers developed a nanoparticle treatment in mice to eliminate certain cells that can drive tissue scarring around tumors and prevent anti-tumor therapies from working. The approach made tumors more sensitive to therapies that boost the immune response to cancer and might one day be applied to humans. The nanoparticle treatment could help immunotherapy work better on lung cancer (red) growing in areas of fibrosis (green). NIH’s National Cancer Institute / Fox Chase Cancer Center Chronic inflammation can fuel a form of scarring called fibrosis linked to cancer. Areas of fibrotic tissues often contain lots of damaged cells that no longer divide nor die off when they should. These “senescent” cells drive inflammation and fibrosis, and they inhibit nearby immune cells. As a result, tumors surrounded by fibrosis are harder to treat with immunotherapies that spur the immune system to attack cancer.